David Roblin

Professor David Roblin is currently Chief Operating Officer at Juvenescence and was previously President of Research and Development at Summit Therapeutics. David served as a Non-executive Director on the Destiny Pharma Ltd Board of Directors from 2011 until May 2017.

He has also served recently as Chief Operating Officer, Chief Medical Officer and President of R&D at Summit Therapeutics plc, Chief Operating Officer and Director of Scientific Translation at the Francis Crick Institute in London from 2014 to 2017 and prior to that, Head of Research, Site Director and Chief Medical Officer for Europe R&D at Pfizer Inc. from 2008 to 2011. From 1997 to 1999, he was Head of Therapy Area for Anti-infectives at Bayer AG. Before entering the life sciences industry, Professor Roblin practised medicine for five years.

Through his career David has remained active in anti-infective R&D and he had key roles in the development of azithromycin, ciprofloxacin, moxiflxacin, celzentry and now ridinilazole. Of note, he was a founder and director of the Innovative Medicines Initiative, which championed precompetitive research including into antibiotics.

David has a first class degree in biochemistry from University of London and later qualified in medicine from St George’s Hospital. He is a Fellow of the Royal College of Physicians, a Fellow of the Faculty of Pharmaceutical Medicine and was recently elected as Fellow of the Academy of Medical Sciences. He is an honorary Professor of Medicine at Swansea University, Professor of Translational Medicine at St George’s and Chair of Scientific Translation at the Francis Crick Institute.